Andy Harrison joins Section 32 from executive leadership roles at Alphabet, including Verily Life Sciences (previously Google Life Sciences) and X (previously GoogleX). Andy brings deep market knowledge and commercial experience to Section 32. As the Head of Business and Corporate Development at Verily, Andy’s team executed global go-to-market campaigns for a wide range of next-generation technologies, building creative and pioneering partnerships, collaborations and joint ventures on a global basis. Andy…
Posted by Tom Zhang, Section 32’s Head of Data
Note: we’re going to start sharing posts on timely topics from subject matter experts on our team when inspiration strikes. First up, our Head of Data Tom weighs in on the startup valuation conversation.
Last week, The Information published an article pointing out the “crazy” rise of startup valuation since the last Global Financial Crisis ended in 2009. According to PitchBook data, the median pre-investment valuation for Series A rounds has increased sixfold to $37 million since 2010. The graph in that article demonstrates the trend. …
While 2020 was a year that no one wants to dwell on, we wanted to share a brief update about our progress and portfolio. We spent the past year thoughtfully building up our team and continuing to invest in areas that we believe can have an outsized positive impact on people’s lives, like early detection of cancer, more efficient and less expensive drug discovery, AI to improve patient experience, more secure cloud computing, and more.
We are particularly interested in the distribution of innovation, not simply innovation itself; we believe that amazing, life-enhancing technologies should be as ubiquitous and easy…
05.20.2020 / News
When I started Section 32 three years ago, I wanted to create a venture fund that could focus on areas where technology can make a real difference on the most important aspects of our lives.
My last job before Section 32 was as founder and CEO at Google Ventures, and even though I loved my time there, I saw a need for a different type of fund — one that could help improve the human condition by accelerating the discovery, development, adoption and distribution of important technologies and lifesaving medicines.
Section 32 is a venture capital fund investing at the frontiers of technology, healthcare and the life sciences.